参考文献

［1] JANUARY C T，WANN L S，CALKINS H，et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation：A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons ［J］. Circulation，2019，140（2）：e125-e151.

［2] OSMANCIK P，HERMAN D，NEUZIL P，et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation ［J］. J Am CollCardiol，2020，75（25）：3122-3135.

［3] LÜSCHER T F. Optimizing management of atrial fibrillation：integrated care，blood pressure control，ablation，and left atrial appendix occlusion ［J］. Eur Heart J，2020，41（30）：2821-2825.

［4] CHUNG M K，ECKHARDT L L，CHEN L Y，et al. Lifestyle and risk factor modification for reduction of atrial fibrillation：A scientific statement from the American Heart Association ［J］. Circulation，2020，141（16）：e750-e772.

［5] BOURIER F，DUCHATEAU J，VLACHOS K，et al. High-power short-duration versus standard radiofrequency ablation：Insights on lesion metrics ［J］. J Cardiovasc Electrophysiol，2018，29（11）：1570-1575.

［6] REDDY V Y，GRIMALDI M，DE POTTER T，et al. Pulmonary vein isolation with very high power，short duration，temperature-controlled lesions：The QDOT-FAST trial ［J］. JACC Clin Electrophysiol，2019，5（7）：778-786.

［7] VALDERRÁBANO M，CHEN H R，SIDHU J，et al. Retrograde ethanol infusion in the vein of Marshall：regional left atrial ablation，vagal denervation and feasibility in humans ［J］. Circ Arrhythm Electrophysiol，2009，2（1）：50-56.

［8] VALDERRÁBANO M，LIU X，SASARIDIS C，et al. Ethanol infusion in the vein of Marshall：Adjunctive effects during ablation of atrial fibrillation ［J］. Heart Rhythm，2009，6（11）：1552-1558.

［9] BÁEZ-ESCUDERO J L，KEIDA T，DAVE A S，et al. Ethanol infusion in the vein of Marshall leads to parasympathetic denervation of the human left atrium：Implications for atrial fibrillation ［J］. J Am Coll Cardiol，2014，63（18）：1892-1901.

［10] HWANG C，WU T J，DOSHI R N，et al. Vein of marshallcannulation for the analysis of electrical activity in patients with focal atrial fibrillation ［J］. Circulation，2000，101（13）：1503-1505.

［11] VALDERRÁBANO M，PETERSON L E，BUNGE R，et al. Vein of Marshall ethanol infusion for persistent atrial fibrillation：VENUS and MARS clinical trial design ［J］. Am Heart J，2019，215：52-61.

［12] BRADLEY C J，HAINES D E. Pulsed field ablation for pulmonary vein isolation in the treatment of atrial fibrillation ［J］. J Cardiovasc Electrophysiol，2020.

［13] REDDY V Y，NEUZIL P，KORUTH J S，et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ［J］. J Am Coll Cardiol，2019，74（3）：315-326.

［14] CHANG S S，HE Y，WANG H，et al. The temporal relation between cardiomyopathy and LBBB and response to cardiac resynchronization therapy：Case series and literature review ［J］. CVIA，2020，4（3）：163-172.

［15] WANG H，HE Y，DU X，et al. Differentiation between left bundle branch block（LBBB）preceded dilated cardiomyopathy and dilated cardiomyopathy preceded LBBB by cardiac magnetic resonance imaging ［J］. Pacing Clin Electrophysiol，2020.

［16] DAI C C，GUO B J，LI W X，et al. Dyssynchronous ventricular contraction in Wolff-Parkinson-White syndrome：a risk factor for the development of dilated cardiomyopathy ［J］. Eur J Pediatr，2013，172（11）：1491-1500.

［17] ZHANG W，HUANG J，QI Y，et al. Cardiac resynchronization therapy by left bundle branch area pacing in patients with heart failure and left bundle branch block ［J］. Heart Rhythm，2019，16（12）：1783-1790.

［18] UPADHYAY G A，VIJAYARAMAN P，NAYAK H M，et al. His corrective pacing or biventricular pacing for cardiac resynchronization in heart failure ［J］. J Am Coll Cardiol，2019，74（1）：157-159.

［19] CHEW D S，KURIACHAN V. Leadless cardiac pacemakers：present and the future ［J］. Curr Opin Cardiol，2018，33（1）：7-13.

［20] SLOTWINER D J，RAITT M H，DEL-CARPIO MUNOZ F，et al. Impact of physiologic pacing versus right ventricular pacing among patients with left ventricular ejection fraction greater than 35%：A systematic review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay：A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society ［J］. Circulation，2019，140（8）：e483-e503.

［21] SHARMA P S，VIJAYARAMAN P，ELLENBOGEN K A. Permanent His bundle pacing：shaping the future of physiological ventricular pacing ［J］. Nat Rev Cardiol，2020，17（1）：22-36.

［22] VIJAYARAMAN P，CHUNG M K，DANDAMUDI G，et al. His bundle pacing ［J］. J Am Coll Cardiol，2018，72（8）：927-947.

［23] TOWBIN J A，MCKENNA W J，ABRAMS D J，et al. 2019 HRS expert consensus statement on evaluation，risk stratification，and management of arrhythmogenic cardiomyopathy：Executive summary ［J］. Heart Rhythm，2019，16（11）：e373-e407.

［24] CHEN L，SONG J，CHEN X，et al. A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression ［J］. Eur Heart J，2019，40（21）：1690-1703.

［25] AL-KHATIB S M，STEVENSON W G，ACKERMAN M J，et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death：A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society ［J］. J Am CollCardiol，2018，72（14）：e91-e220.

［26] KHERA A V，MASON-SUARES H，BROCKMAN D，et al. Rare genetic variants associated with sudden cardiac death in adults ［J］. J Am Coll Cardiol，2019，74（21）：2623-2634.

［27] FELLMANN F，VAN EL C G，CHARRON P，et al. European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death ［J］. Eur J Hum Genet，2019，27（12）：1763-1773.

［28] KAMP N J，AL-KHATIB S M. The subcutaneous implantable cardioverter-defibrillator in review［J］. Am Heart J，2019，217：131-139.

［29] VAN DIJK V F，BOERSMA L V. The subcutaneous implantable cardioverter defibrillator in 2019 and beyond ［J］. Trends Cardiovasc Med，2020，30（6）：378-384.

［30] OLGIN J E，PLETCHER M J，VITTINGHOFF E，et al. Wearable cardioverter-defibrillator after myocardial infarction ［J］. N Engl J Med，2018，379（13）：1205-1215.

［31] CANNATÀ A，DE ANGELIS G，BOSCUTTI A，et al. Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction ［J］. Heart，2020，106（9）：656-664.

［32] GRÄNI C，BENZ D C，GUPTA S，et al. Sudden cardiac death in ischemic heart disease：From imaging arrhythmogenic substrate to guiding therapies ［J］. JACC Cardiovasc Imaging，2019.